57% Pakistanis as compared to 72% Britons don’t expect to live to be 100 years old: Gallup and Gilani Pakistan 

Islamabad, December 08, 2022 (PPI-OT):According to a survey conducted by Gallup and Gilani Pakistan, 57% Pakistanis as compared to 72% Britons don’t expect to live to be 100 years old.

A nationally representative sample of adult men and women from across the country was asked the following question regarding, “To what extent do you agree or disagree with the following statements? – I expect I Will live to be 100 years old” 8% said that they totally agree, 19% said that they somewhat agree, 18% responded somewhat disagree while 39% responded totally disagree.

Comparison between Pakistan and Britain: The same question was asked in Britain by IPSOS (the study can be found here) and in response, 14% said that they expect that they will live to be 100 years old while 72% disagreed with the statement. 13% more Pakistanis than British people said that they expect they will live to be 100 years old.

Question: “To what extent do you agree or disagree with the following statements? – I expect I Will live to be 100 years old”

For more information, contact:
Head Office,
Gallup Pakistan
Islamabad, Pakistan
Tel: +92-51-8445080
Email: isb@gallup.com.pk, caf@gallup.com.pk
Website: www.gallup.com.pk

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

The Albert B. Sabin Gold Medal and Rising Star Award

The Sabin Vaccine Institute awarded R&D leader Dr. Kathrin Jansen the 2022 Gold Medal for her extraordinary contributions to vaccinology. Immunologist Dr. Kizzmekia Corbett received the 2022 Rising Star award for her work advancing the field of immunization.

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

The Gold Medal, now in its 29th year, is Sabin’s highest scientific honor, given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege, and Myron Levine.

Dr. Jansen was selected for her nearly three decades of commitment to advancing vaccine research and development (R&D) for a range of challenging diseases from COVID-19 to HPV and pneumonia, all of which afflict adults and children in low-and middle-income countries with already fragile health care systems.

This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc. There, Dr. Jansen led global vaccines R&D with responsibilities ranging from discovery to post-marketing commitments. In collaboration with BioNTech, Dr. Jansen spearheaded the development of a COVID-19 vaccine that would become the first FDA and WHO-authorized COVID-19 vaccine and is the first-ever approved vaccine to use an mRNA platform.

Dr. Jansen’s leadership at Pfizer also produced newer versions of a widely used pneumococcal conjugate vaccine and vaccine candidates to prevent Streptococcus pneumoniae, respiratory syncytial virus (RSV), meningococcal infections, and Group B streptococcus. Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine. She also contributed to programs for rotavirus, mumps, measles and rubella.

“We are delighted to recognize Dr. Jansen with our Gold Medal award for her commitment to furthering vaccines and tackling tough scientific challenges in the interest of benefitting humanity and saving lives,” says Amy Finan, Sabin’s chief executive officer. “Throughout her career, she has demonstrated a unique passion for answering perplexing research questions and making bold decisions that led to impactful public health milestones.”

Dr. Jansen said she was “humbled” by the honor. “When you look at all the previous Gold Medal recipients, they are colleagues and friends that you know and have interacted and worked with for years – passionate people, all dedicated to making a healthier world.”

Sabin’s Rising Star Dr. Corbett is an assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. A viral immunologist by training, Dr. Corbett works to advance vaccine development for pandemic preparedness and to build public confidence in vaccines, particularly among communities of color facing health disparities. While at the National Institutes of Health she was a member of the team whose research on the novel coronavirus laid the groundwork for the COVID-19 Moderna vaccine – the first candidate to be tested in Phase 1 clinical trials in the U.S.

Dr. Corbett’s research has also included a universal influenza vaccine, dengue, and respiratory syncytial virus. Currently, she leads a laboratory focused on novel coronaviruses and other infectious diseases that aims to inform vaccine development against potential future pandemics. She is also a leading advocate for STEM education, health care equity, and community-based public health outreach.

“Sabin is delighted to name Dr. Corbett this year’s Rising Star,” says Finan. “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics. She has done incredible work explaining the scientific rigor behind vaccines and is inspiring the next generation of researchers and public health heroes.”

“It’s a really big honor for me to win this award,” says Dr. Corbett. “Having just started my career and my own lab, winning this Rising Star Award suggests that – number one – I have a long way to go but – number two – that I am capable, which is especially good to hear from my peers, mentors and other more experienced scientists.”

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.

For more information, visit https://www.sabin.org/ and follow us on Twitter @sabinvaccine.

Media contact: Rajee Suri, rajee.suri@sabin.org

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8708580

یونیورسٹی آف ٹیکنالوجی سڈنی اور کرکٹ این ایس ڈبلیو مقامی اور بین الاقوامی کرکٹ کمیونیٹیز کو فائدہ پہنچانے کے لئے اسٹریٹجک شراکت داری میں شامل ہوگئی

سڈنی، 8 دسمبر 2022ء/پی آرنیوزوائر/– یونیورسٹی آف ٹیکنالوجی سڈنی (یو ٹی ایس) کرکٹ این ایس ڈبلیو (سی این ایس ڈبلیو) کے ساتھ مل کر کرکٹ لیب کا آغاز کر رہی ہے، جس کا مقصد  کرکٹ اور یو ٹی ایس دونوں کے لیے جدید تحقیق کرنا اور نئے امکانات تلاش کرنا ہے۔

یو ٹی ایس کے ڈپٹی وائس چانسلر آف انٹرپرائز پروفیسر گلین ویٹ وک کا کہنا ہے کہ یہ تعاون، جو یو ٹی ایس کی مہارت کو کرکٹ کمیونیٹی کو درپیش چیلنجوں پر لاگو کرتا ہے، عوامی فائدے کے لئے حقیقی دنیا کے مسائل کو حل کرنے کے لئے یونیورسٹی کے مشن کے ساتھ مطابقت رکھتا ہے۔

توقع ہے کہ پانچ سالہ اسٹریٹجک تعاون سے مقامی اور عالمی سطح پر اثرات مرتب ہوں گے۔ یہ ایلیٹ پرفارمنس، پری ایلیٹ اور کمیونٹی کرکٹ میں تحقیق، تعلیم اور جدت طرازی کو شامل کرے گا۔

یو ٹی ایس اسکول آف اسپورٹ، ایکسرسائز اینڈ ری ہیبلیٹیشن کے ممتاز پروفیسر ایرون کوٹس نے کہا کہ بائیو مکینکس کے استعمال سے لے کر کارکردگی اور چوٹ کے خطرے سے وابستہ عوامل کی نشاندہی کرنے سے لے کر کھیل سائنس اور ٹکنالوجی اسکول، کمیونٹی اور پیشہ ورانہ کھیلوں کو محفوظ بنانے کے طریقوں کو تلاش کرنے تک، یہ شراکت داری بالآخر ہمارے کھلاڑیوں کی صحت کو بہتر بنانے کے لئے شواہد پر مبنی طریقے تیار کرے گی۔

کرکٹ این ایس ڈبلیو کے سی ای او لی جرمون نے کہا کہ اس تعاون سے کرکٹ کے مستقبل پر بہت اثر پڑے گا۔

ان کا کہنا تھا کہ کچھ کام سے ہمیں کرکٹ کھیلنے والے 5 سے 12 سال کے بچوں کی تعداد کو دوگنا کرنے کے ہدف میں مدد ملے گی، لیکن 130 پروجیکٹ یا پاتھ ویز اور پریمیئر کرکٹ کے لیے ہمارے سپورٹ نیٹ ورکس کو مضبوط بنانے جیسے دیگر شعبے بھی ہوں گے جن کے نہ صرف ہماری ٹیموں بلکہ آسٹریلوی کرکٹ کی کامیابی پر دور رس اثرات مرتب ہوسکتے ہیں۔

یہ شراکت داری سی این ایس ڈبلیو کے ساتھ یو ٹی ایس کے موجودہ تعلقات پر مبنی ہے۔ یو ٹی ایس ڈیٹا سائنس انسٹی ٹیوٹ (ڈی ایس آئی) مشین لرننگ اور کلسٹرنگ تکنیک کا استعمال کرتے ہوئے اسکول ، کلب اور نمائندہ کرکٹ کے ذریعے کرکٹرز کے سفر کا تجزیہ کرنے کے لئے سی این ایس ڈبلیو کے ساتھ مل کر کام کر رہا ہے۔

یو ٹی ایس ڈی ایس آئی کے ڈپٹی ڈائریکٹر ایسوسی ایٹ پروفیسر ایڈم بیری نے کہا کہ ڈیٹا سائنس انسٹی ٹیوٹ این ایس ڈبلیو کرکٹ کمیونٹی کے لئے جدید ترین مصنوعی ذہانت کی فراہمی کے لئے دلچسپ نئے طریقوں کی تلاش کا منتظر ہے۔

یونیورسٹی آف ٹیکنالوجی سڈنی ٹیکنالوجی کی ایک معروف یونیورسٹی ہے ، جو کمپیوٹر سائنس ، انجینئرنگ اور اے آئی ریسرچ کے لئے آسٹریلیا میں نمبر 1 پر ہے۔

عالمی سطح پر یونیورسٹی کے اثرات کے بارے میں مزید جانیں: discover.uts.edu.au

University of Technology Sydney and Cricket NSW join forces in strategic partnership to benefit local and international cricket communities

SYDNEY, Dec. 8, 2022 /PRNewswire/ — The University of Technology Sydney (UTS) is collaborating with Cricket NSW (CNSW) to launch The Cricket Lab, a partnership aimed at creating innovative research and exploring new possibilities for both cricket and UTS.

“This collaboration, which applies UTS’s expertise to the challenges facing the cricket community, aligns with the university’s mission to solve real world problems for the public benefit,” says Professor Glenn Wightwick, UTS Deputy Vice Chancellor of Enterprise.

The five-year strategic collaboration is expected to deliver local and global impact. It will engage research, education and innovation across elite performance, pre-elite and community cricket.

“From using biomechanics identifying factors associated with performance and injury risk, to finding ways sport science and technology can make school, community and professional sport safer, this partnership will ultimately develop evidence-based methods for improving the health of our athletes,” said Distinguished Professor Aaron Coutts from the UTS School of Sport, Exercise and Rehabilitation.

Cricket NSW  CEO Lee Germon said the benefits of the collaboration would have a big impact on the future of cricket.

“Some of the work will help us in our goal of doubling the number of 5-12 year olds playing cricket, but there will be other areas like the 130 Project or the strengthening of our support networks for Pathways and Premier Cricket that could have far-reaching effects on the success of not only our teams, but Australian cricket as well.”

The partnership builds on UTS’s existing relationship with CNSW. The UTS Data Science Institute (DSI) has been working closely with CNSW to analyse the journey of cricketers through school, club and representative cricket by using machine learning and clustering techniques.

“The Data Science Institute is looking forward to exploring exciting new ways to deliver cutting-edge artificial intelligence for the NSW cricket community,” said Associate Professor Adam Berry, Deputy Director of UTS DSI.

The University of Technology Sydney is a leading university of technology, ranked #1 in Australia for Computer Science, Engineering and AI Research. Learn more about the university’s impact globally at discover.uts.edu.au.